Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 4/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL687569 | 0.86 | TAAR1 (0.41) | PRCPSLC22A1ADRA1AADRA2AADRA1D | |
| SCHEMBL3263413 | 0.76 | PRCP (0.60) | PRCPSLC22A1RECQLOPRM1GAA | |
| SCHEMBL769614 | 0.75 | ADRA1A (0.57) | ADRA1AADRA2AADRA1DADRA1BOPRM1 | |
| SCHEMBL29768314 | 0.74 | PRCP (1.00) | PRCPSLC22A1OPRM1GAASMN1; SMN2 | |
| SCHEMBL5284097 | 0.74 | PRCP (1.00) | PRCPSLC22A1OPRM1GAASMN1; SMN2 | |
| SCHEMBL4160731 | 0.74 | PRCP (1.00) | PRCPSLC22A1OPRM1GAASMN1; SMN2 | |
| SCHEMBL5812041 | 0.74 | PRCP (1.00) | PRCPSLC22A1OPRM1GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8823234 | 0.73 | PRCP (0.97) | PRCPSLC22A1OPRM1GAASMN1; SMN2 | |
| Water SCHEMBL28203568 | 0.73 | PRCP (0.97) | PRCPSLC22A1OPRM1GAASMN1; SMN2 | |
| SCHEMBL10931837 | 0.73 | ADRA1A (0.50) | ADRA1AADRA2AADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849644-B2 | Isoquinoline derivatives useful in the treatment of CNS disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-02-01 | — | — | US | disclosed |
| US-20040053956-A1 | Isoquinoline derivatives useful in the treatment of cns disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-18 | — | — | US | disclosed |
| EP-1341783-A1 | ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002042293-A1 | ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053956-A1 | Isoquinoline derivatives useful in the treatment of cns disorders | INA, NLN, GRIN2C | PRCP 2309/4885SLC22A1 2828/4885ADRA1A 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.